CAAR Mumbai Clarifies 5% IGST Applicability on Import of Veterinary Bulk Drugs
Introduction to the Classification Conundrum
The intersection of customs tariff classifications and integrated tax rate notifications frequently creates complex interpretive challenges for importers. A recurring dispute arises when a product can theoretically be classified under a general chemical chapter based on its chemical composition, while simultaneously fitting the description of a specific end-use category, such as pharmaceuticals or medicines, under a distinct tax rate notification. This exact legal friction was recently addressed by the Customs Authority for Advance Ruling (CAAR) in Mumbai.
In the landmark advance ruling of In re Huvepharma Sea (Pune) Private Limited, the authority was tasked with determining the appropriate Integrated Goods and Services Tax (IGST) rate applicable to specific high-purity Active Pharmaceutical Ingredients (APIs) intended strictly for veterinary applications. The core dispute revolved around whether these imported bulk drugs should be taxed at a general rate of 18% as organic chemicals or at a concessional rate of 5% as explicitly described drugs and medicines. This ruling provides profound clarity for the pharmaceutical and veterinary sectors regarding the interpretation of description-based tax entries versus chapter-based tariff entries.
Factual Matrix of the Case
Profile of the Assessee and the Imported Goods
The applicant in this matter, M/s Huvepharma Sea (Pune) Pvt. Ltd., holding IEC No. AACCH3097H, is an established entity engaged in the manufacturing and supply chain of animal health and nutritional commodities, with a specific focus on antibiotic formulations. Seeking statutory certainty regarding their tax liabilities, the assessee filed an application in Form CAAR-1 before the Secretary of the Customs Authority for Advance Ruling, Mumbai. The application, comprehensively supported by relevant enclosures, was officially received on 08.06.2026 under the provisions of Section 28H(1) of the Customs Act, 1962.
The assessee sought a definitive advance ruling concerning the import of two specific bulk drugs:
- Clopidol (VET): A pyridinol derivative fundamentally utilized as a coccidiostat.
- Amprolium 100% (VET): An active agent deployed specifically against coccidial parasites.
Both products were categorically described as high-purity Active Pharmaceutical Ingredients (APIs) manufactured exclusively for veterinary consumption. Their primary therapeutic application is the prevention, management, and treatment of coccidiosis, a severe parasitic disease prevalent in poultry.